EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference.
Mr. Hughes and Mr. Sitko will present on Monday, September 8, 2025 at 9:00 AM ET. The webcast for the presentation can be accessed by visiting https://bit.ly/4mjFgkY. XOMA Royalty’s presentation can be also accessed by visiting the investor relations section of the Company’s website at www.xoma.com.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
| XOMA Investor Contact | XOMA Media Contact | 
| Juliane Snowden | Kathy Vincent | 
| XOMA Royalty | KV Consulting & Management | 
| +1 646-438-9754 | This email address is being protected from spambots. You need JavaScript enabled to view it. | 
| This email address is being protected from spambots. You need JavaScript enabled to view it. | 

| Last Trade: | US$33.06 | 
| Daily Change: | 0.08 0.24 | 
| Daily Volume: | 30,289 | 
| Market Cap: | US$399.700M | 
 August 13, 2025  August 04, 2025  May 13, 2025  | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load